Acorda Therapeutics Inc.ACOR-Recently filed Operating Results (10-Q)
Acorda Therapeutics Inc
Rochester,NY 8/29/2009 02:57 PM GMT (TransWorldNews)
Aug 10, 2009, Acorda Therapeutics Inc. (ACOR) recently filed Quarterly Report for the period ended 2009-06-30.
Acorda Therapeutics is commercial-stage biopharmaceutical company focused on the identification development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company\'s lead product candidate Fampridine-SR for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury multiple sclerosis and related conditions of the nervous system. Acorda Therapeutics Inc. has a market cap of $904.31 million; its shares were traded at around $23.79 with and P/S ratio of 18.91.
Highlight of Business Operations:
We recorded discounts and allowances of $2.2 million for the three-month period ended June 30, 2009 as compared to $1.7 million for the three-month period ended June 30, 2008. Discounts and allowances are recorded when Zanaflex Capsules and Zanaflex tablets are shipped to wholesalers.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
info@stockeinstein.com
StockEinstein.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
ACOR
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
